The H-FFC Cl4 mouse develops severe NASH with bridging fibrosis within 12 weeks
- Mice are maintained on a diet high in fat, fructose and cholesterol (H-FFC) and dosed with CCl4 for 12 weeks
- The H-FFC CCl4 mouse develops all the clinical histological endpoints associated with NASH including bridging fibrosis
- Liver bioanalysis confirms the histological findings
- Plasma AST is significantly increased
The H-FFC CCl4 mouse develops severe NASH and bridging fibrosis
Histopathology scoring of standard chow and H-FFC CCl4 mice. Data are presented as individual animal scores and means ± SEM.
Significant differences versus the standard chow vehicle group are denoted by ***p<0.001. The NAFLD activity score (NAS) was calculated by combining the scores for # parameters.
Sirius red stained liver – demonstrating the presence of bridging fibrosis
Histological endpoints are confirmed with liver bioanalysis, indicated by a significant increase in collagen, triglyceride and cholesterol content in the H-FFC CCl4. Plasma levels of the liver enzyme ALT is also significantly increased.
Liver biochemistry and terminal plasma analysis of standard chow and H-FFC CCl4 mice.
Data are expressed as the means and SEM. Significant differences versus the standard chow group are denoted by **p<0.01 and ***p<0.001.
Get in touch to learn more about RenaSci’s H-FFC CCl4 mouse model of NASH and fibrosis.
Explore our other models of NASH